Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L LINDSAY

Showing results (331-340 of 346) with videos related to

Pageof 35
Sort By:
Hepatology (Baltimore, Md.)|September 26, 2008
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis CChihiro Morishima, Timothy R Morgan, James E Everhart, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis CNeal D Freedman, James E Everhart, Karen L Lindsay, et al.
Journal of Hepatology|September 2, 2005
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C TrialAdrian M Di Bisceglie, Richard K Sterling, Raymond T Chung, et al.
Nature Cell Biology|November 24, 2015
Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastomaSaverio Tardito, Anaïs Oudin, Shafiq U Ahmed, et al.
Hepatology (Baltimore, Md.)|November 1, 1996
Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy GroupK L Lindsay, G L Davis, E R Schiff, et al.
Hepatology (Baltimore, Md.)|April 27, 2011
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis CJules L Dienstag, Marc G Ghany, Timothy R Morgan, et al.
Journal of Child and Adolescent Psychopharmacology|December 29, 2005
Acute and long-term safety and tolerability of risperidone in children with autismMichael G Aman, L Eugene Arnold, Christopher J McDougle, et al.
Frontiers in Nutrition|October 16, 2025
Defining the evolving field of culinary medicine across multiple domainsCaitlin A Hildebrand, Kristi E Artz, Beth Dollinger, et al.
Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
Angewandte Chemie (International Ed. in English)|August 21, 2025
Fragment-Based Drug Discovery of Novel High-affinity, Selective, and Anti-inflammatory Inhibitors of the Keap1-Nrf2 Protein-Protein InteractionChunyu Lin, Dilip Narayanan, Marilia Barreca, et al.
Pageof 35

Showing results (331-340 of 346) with videos related to

Sort By:
Pageof 35
Hepatology (Baltimore, Md.)|September 26, 2008
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis CChihiro Morishima, Timothy R Morgan, James E Everhart, et al.
Hepatology (Baltimore, Md.)|August 14, 2009
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis CNeal D Freedman, James E Everhart, Karen L Lindsay, et al.
Journal of Hepatology|September 2, 2005
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C TrialAdrian M Di Bisceglie, Richard K Sterling, Raymond T Chung, et al.
Nature Cell Biology|November 24, 2015
Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastomaSaverio Tardito, Anaïs Oudin, Shafiq U Ahmed, et al.
Hepatology (Baltimore, Md.)|November 1, 1996
Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy GroupK L Lindsay, G L Davis, E R Schiff, et al.
Hepatology (Baltimore, Md.)|April 27, 2011
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis CJules L Dienstag, Marc G Ghany, Timothy R Morgan, et al.
Journal of Child and Adolescent Psychopharmacology|December 29, 2005
Acute and long-term safety and tolerability of risperidone in children with autismMichael G Aman, L Eugene Arnold, Christopher J McDougle, et al.
Frontiers in Nutrition|October 16, 2025
Defining the evolving field of culinary medicine across multiple domainsCaitlin A Hildebrand, Kristi E Artz, Beth Dollinger, et al.
Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
Angewandte Chemie (International Ed. in English)|August 21, 2025
Fragment-Based Drug Discovery of Novel High-affinity, Selective, and Anti-inflammatory Inhibitors of the Keap1-Nrf2 Protein-Protein InteractionChunyu Lin, Dilip Narayanan, Marilia Barreca, et al.
Pageof 35